Back to today’s briefing

Story perspectives

Eli Lilly's $1.3B Acquisition Boosts Verve Stock 73%

6/17/2025

50 10

Summary

Story summary

Eli Lilly is set to acquire Verve Therapeutics for up to $1.3 billion, sending Verve's stock soaring by over 73%. The deal promises $10.50 per share, plus additional payments tied to Verve's promising drug in Phase 3 trials. This strategic move underscores Lilly's dedication to pioneering gene-editing innovations in cardiovascular care.

1 of 1

Story summary

Eli Lilly is set to acquire Verve Therapeutics for up to $1.3 billion, sending Verve's stock soaring by over 73%. The deal promises $10.50 per share, plus additional payments tied to Verve's promising drug in Phase 3 trials. This strategic move underscores Lilly's dedication to pioneering gene-editing innovations in cardiovascular care.